External validation of deep learning-derived 18F-FDG PET/CT delta biomarkers for loco-regional control in head and neck cancer

Delta biomarkers that reflect changes in tumour burden over time can support personalised follow-up in head and neck cancer. However, their clinical use can be limited by the need for manual image segmentation. This study externally evaluates a deep learning model for automatic determination of volume change from serial 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scans to stratify patients by loco-regional outcome. Patient/material and methods: An externally developed deep learning algorithm for tumour segmentation was applied to pre- and post-radiotherapy (RT, with or without concomitant chemoradiotherapy) PET/CT scans of 50 consecutive head and neck cancer patients from The Christie NHS Foundation Trust, UK. The model, originally trained on pre-treatment scans from a different institution, was deployed to derive tumour volumes at both time points. The AI-derived change in tumour volume (ΔPET-Gross tumour volume (GTV)) was calculated for each patient. Kaplan-Meier analysis assessed loco-regional control based on ΔPET-GTV, dichotomised at the cohort median. In a separate secondary analysis confined to the pre‑treatment scans, a radiation oncologist qualitatively evaluated the AI‑generated PET‑GTV contours.

Patients with higher ΔPET-GTV (i.e. greater tumour shrinkage) had significantly improved loco-regional control (log-rank p = 0.02). At 2 years, control was 94.1% (95% CI: 83.6-100%) vs. 53.6% (95% CI: 32.2-89.1%). Only one of nine failures occurred in the high ΔPET-GTV group. Clinician review found AI volumes acceptable for planning in 78% of cases. In two cases, the algorithm identified oropharyngeal primaries on pre-treatment PET-CT before clinical identification.

Deep learning-derived ΔPET-GTV may support clinically meaningful assessment of post-treatment disease status and risk stratification, offering a scalable alternative to manual segmentation in PET/CT follow-up.